z-logo
Premium
Usefulness of endoscopic biopsy using immunostaining of p53 and Ki‐67 in tumors of the ampulla of Vater
Author(s) -
Kubota Kensuke,
Kakuta Yukio,
Kawamura Shunji,
Saito Shuichi,
Seki Hideichi,
Kuniyoshi Takashi
Publication year - 2003
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1046/j.1440-1827.2003.01482.x
Subject(s) - ampulla of vater , ampulla , immunostaining , pathology , medicine , biopsy , immunohistochemistry , anatomy , carcinoma
We investigated the diagnostic and prognostic value of p53 expression and proliferative activity, as indicated by the Ki‐67, in endoscopic biopsy specimens. Specimens were immunologically stained with p53 and MIB‐1 (Ki‐67), and the MIB‐1/Ki‐67 labeling index (LI) was calculated. Classification of adenomas was based on findings of H&E‐stained preparations into those with low‐ or high‐grade atypia. Well‐differentiated tubular and papillary adenocarcinomas were classified as carcinomas with low‐ or high‐grade atypia. There were significant differences among the control and adenoma patients in MIB‐1/Ki‐67 LI ( P  < 0.05). No significant difference was identified between adenomas with high grade atypia and carcinomas with low grade atypia. The p53 expression was negative in all adenomas, but it was positive in 68.2% of carcinomas. The current study demonstrated that p53 protein expression in endoscopic biopsy specimens was of preoperative diagnostic value for carcinoma of the ampulla of Vater. The p53 protein positive tumors had a relatively higher malignant potential than p53 protein negative ones. The MIB‐1/Ki‐67 LI was useful in differentiating non‐tumorous lesions from adenomas and adenomas with low‐ or high‐grade atypia. The MIB‐1/Ki‐67 LI had a prognostic value because clinicopathological factors of carcinoma of ampulla of Vater correlated with MIB‐1/Ki‐67 LI.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here